Drotrecogin Alfa (Activated) Treatment in Severe Sepsis From the Global Open-Label Trial ENHANCE: Further Evidence for Survival and Safety and Implications for Early Treatment

ENHANCE supports the evidence of the favorable benefit-risk ratio observed in PROWESS and suggests that more effective use of drotrecogin alfa (activated) may be obtained by earlier therapy initiation

Continue to Drotrecogin Alfa (Activated) Treatment in Severe Sepsis From the Global Open-Label Trial ENHANCE: Further Evidence for Survival and Safety and Implications for Early Treatment on Medscape Headlines.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz